Furthermore, one study showed that initial treatment with the combination of a BRAF and MEK inhibitors can prevent or delay emergence of resistance due to ERK pathway reactivation in BRAF mutant melanomas [54]. The gene discussed is MAP2K7; the disease is melanoma.